Back to Search Start Over

The Copenhagen Triage Algorithm is non-inferior to a traditional triage algorithm: A cluster-randomized study.

Authors :
Hasselbalch RB
Pries-Heje M
Schultz M
Plesner LL
Ravn L
Lind M
Greibe R
Jensen BN
Høi-Hansen T
Carlson N
Torp-Pedersen C
Rasmussen LS
Iversen K
Source :
PloS one [PLoS One] 2019 Feb 04; Vol. 14 (2), pp. e0211769. Date of Electronic Publication: 2019 Feb 04 (Print Publication: 2019).
Publication Year :
2019

Abstract

Introduction: Triage systems with limited room for clinical judgment are used by emergency departments (EDs) worldwide. The Copenhagen Triage Algorithm (CTA) is a simplified triage system with a clinical assessment.<br />Methods: The trial was a non-inferiority, two-center cluster-randomized crossover study where CTA was compared to a local adaptation of Adaptive Process Triage (ADAPT). CTA involves initial categorization based on vital signs with a final modification based on clinical assessment by an ED nurse. We used 30-day mortality with a non-inferiority margin at 0.5%. Predictive performance was compared using Receiver Operator Characteristics.<br />Results: We included 45,347 patient visits, 23,158 (51%) and 22,189 (49%) were triaged with CTA and ADAPT respectively with a 30-day mortality of 3.42% and 3.43% (P = 0.996) a difference of 0.01% (95% CI: -0.34 to 0.33), which met the non-inferiority criteria. Mortality at 48 hours was 0.62% vs. 0.71%, (P = 0.26) and 6.38% vs. 6.61%, (P = 0.32) at 90 days for CTA and ADAPT. CTA triaged at significantly lower urgency level (P<0.001) and was superior in predicting 30-day mortality, Area under the curve: 0.67 (95% CI 0.65-0.69) compared to 0.64 for ADAPT (95% CI 0.62-0.66) (P = 0.03). There were no significant differences in rate of admission to the intensive care unit, length of stay, waiting time nor rate of readmission within 30 or 90 days.<br />Conclusion: A novel triage system based on vital signs and a clinical assessment by an ED nurse was non-inferior to a traditional triage algorithm by short term mortality, and superior in predicting 30-day mortality.<br />Trial Registration: Clinicaltrials.gov NCT02698319.<br />Competing Interests: Dr. Torp-Pedersen reports grants and personal fees from Bayer, grants from Biotronic, outside the submitted work.

Details

Language :
English
ISSN :
1932-6203
Volume :
14
Issue :
2
Database :
MEDLINE
Journal :
PloS one
Publication Type :
Academic Journal
Accession number :
30716123
Full Text :
https://doi.org/10.1371/journal.pone.0211769